Research programme: omega-3-fatty acid therapeutics - Matinas BioPharma

Drug Profile

Research programme: omega-3-fatty acid therapeutics - Matinas BioPharma

Alternative Names: MAT-8800

Latest Information Update: 19 May 2015

Price : $50

At a glance

  • Originator Matinas BioPharma
  • Class Omega 3 fatty acids
  • Mechanism of Action Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fatty liver

Most Recent Events

  • 01 Nov 2014 Matinas BioPharma receives patent allowance for Methods of Administering Compositions Comprising Docosapentaenoic Acid in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top